SEMA4D and postmenopausal osteoporosis: The injection of a blocking antibody against Semaphorin 4D prevented bone loss due to ovariectomy in a postmenopausal mouse model, suggesting that the Semaphorin 4D–Plexin-B1 interaction is important for the pathogenesis of postmenopausal osteoporosis.